Figure 1From: Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survivalTreatment schedule: 5-FU + docetaxel + radiotherapy.Back to article page